Sheila obtained an HNC in Medical Laboratory Sciences, working in a NHS Haematology and Blood Serology Laboratory, before switching to research at the Insitute of Zoology in London. She subsequently moved to the Medical Research Council’s Reproductive Health Unit in Edinburgh until her move in 2011 to a position as a Research Technician in Dr Andy South’s lab, where as well as providing general support assessed the effect of PLK inhibitors in vitro and in vivo on squamous cell carcinoma. In 2014 she joined Dr Sara Browns group to develop an organotypic model of eczema and study target genes highlighted in Dr Browns previous work.
Genetic mechanisms in atopic eczema
Atopic eczema is an itchy inflammatory skin disease, which has increased in prevalence over recent decades. It is a complex trait, arising from the interaction of multiple genetic and environmental factors, but eczema is highly heritable, demonstrating the importance of genetic predisposition.
Multiple risk loci have been identified by genomewide association studies, but a locus on chromosome 1q21 shows the strongest association. Within this locus, loss-of-function mutations in the gene encoding the skin barrier protein filaggrin (FLG) are well known to increase risk of atopic eczema. Dr Brown’s work, in collaboration with Irwin McLean and Alan Irvine, has contributed to defining the role of FLG in every step of the ‘atopic march’, including mild, moderate and severe eczema, atopic asthma, allergic rhinitis and peanut allergy. Her work has shown that copy number variation within FLG has a dose-dependent effect on eczema risk, indicating that treatments aimed at increasing filaggrin expression may be of therapeutic benefit.
Ng YZ, Pourreyron C, Salas-Alanis JC, Dayal JH, Cepeda-Valdes R, Yan W, Wright S, Chen M, Fine JD, Hogg FJ, McGrath JA, Murrell DF, Leigh IM, Lane EB, South AP: Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa, Cancer Res 2012, 72:3522-3534
Catalano RD, Wilson MR, Boddy SC, Jabbour HN: Comprehensive expression analysis of prostanoid enzymes and receptors in the human endometrium across the menstrual cycle, Mol Hum Reprod 2011, 17:182-192
Catalano RD, Wilson MR, Boddy SC, McKinlay AT, Sales KJ, Jabbour HN: Hypoxia and prostaglandin E receptor 4 signalling pathways synergise to promote endometrial adenocarcinoma cell proliferation and tumour growth, PLoS One 2011, 6:e19209
Macdonald LJ, Boddy SC, Denison FC, Sales KJ, Jabbour HN: A role for lipoxin A(4) as an anti-inflammatory mediator in the human endometrium, Reproduction 2011, 142:345-352
Sales KJ, Boddy SC, Jabbour HN: F-prostanoid receptor alters adhesion, morphology and migration of endometrial adenocarcinoma cells, Oncogene 2008, 27:2466-2477
Sales KJ, Boddy SC, Williams AR, Anderson RA, Jabbour HN: F-prostanoid receptor regulation of fibroblast growth factor 2 signaling in endometrial adenocarcinoma cells, Endocrinology 2007, 148:3635-3644
Jabbour HN, Sales KJ, Smith OP, Battersby S, Boddy SC: Prostaglandin receptors are mediators of vascular function in endometrial pathologies, Mol Cell Endocrinol 2006, 252:191-200
Jabbour HN, Sales KJ, Boddy SC, Anderson RA, Williams AR: A positive feedback loop that regulates cyclooxygenase-2 expression and prostaglandin F2alpha synthesis via the F-series-prostanoid receptor and extracellular signal-regulated kinase 1/2 signaling pathway, Endocrinology 2005, 146:4657-4664
Jabbour HN, Boddy SC: Prostaglandin E2 induces proliferation of glandular epithelial cells of the human endometrium via extracellular regulated kinase 1/2-mediated pathway, J Clin Endocrinol Metab 2003, 88:4481-4487
Battersby S, Boddy SC, Critchley HO, Jabbour HN: Expression and localization of endothelial monocyte-activating polypeptide II in the human endometrium across the menstrual cycle: regulation of expression by prostaglandin E(2), J Clin Endocrinol Metab 2002, 87:3928-3935
Jabbour HN, Kelly RW, Boddy SC: Autocrine/paracrine regulation of apoptosis in epithelial cells by prostaglandin E2, Prostaglandins Leukot Essent Fatty Acids 2002, 67:357-363 Jabbour HN, Milne SA, Williams AR, Anderson RA, Boddy SC: Expression of COX-2 and PGE synthase and synthesis of PGE(2)in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors, Br J Cancer 2001, 85:1023-1031 Milne SA, Perchick GB, Boddy SC, Jabbour HN: Expression, localization, and signaling of PGE(2) and EP2/EP4 receptors in human nonpregnant endometrium across the menstrual cycle, J Clin Endocrinol Metab 2001, 86:4453-4459
Jabbour HN, Critchley HO, Yu-Lee LY, Boddy SC: Localization of interferon regulatory factor-1 (IRF-1) in nonpregnant human endometrium: expression of IRF-1 is up-regulated by prolactin during the secretory phase of the menstrual cycle, J Clin Endocrinol Metab 1999, 84:4260-4265
Jabbour HN, Critchley HO, Boddy SC: Expression of functional prolactin receptors in nonpregnant human endometrium: janus kinase-2, signal transducer and activator of transcription-1 (STAT1), and STAT5 proteins are phosphorylated after stimulation with prolactin, J Clin Endocrinol Metab 1998, 83:2545-2553
Jabbour HN, Boddy SC, Lincoln GA: Pattern and localisation of expression of vascular endothelial growth factor and its receptor flt-1 in the ovine pituitary gland: expression is independent of hypothalamic control, Mol Cell Endocrinol 1997, 134:91-100
Shaw HJ, Boddy SE, Hodges JK: Developmental changes in marmoset granulosa cell responsiveness to insulin-like growth factor-I: interactions with follicle-stimulating hormone and estradiol, Biol Reprod 1993, 49:568-576